Details of the Drug

General Information of Drug (ID: DM9LNXS)

Drug Name
ARI-3037MO
Indication
Disease Entry ICD 11 Status REF
Cardiovascular disease BA00-BE2Z Phase 2 [1]
Dyslipidemia 5C80-5C81 Phase 2 [2]
Hypertriglyceridemia 5C80.1 Phase 2 [1]
Cross-matching ID
TTD ID
D01VMZ
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Diacylglycerol O-acyltransferase 2 (DGAT2) TTRHEQ4 DGAT2_HUMAN Inhibitor [3]
Hydroxycarboxylic acid receptor 3 (HCAR3) TT8WFXV HCAR3_HUMAN Agonist [1]
Nicotinic acid receptor (HCAR2) TTWNV8U HCAR2_HUMAN Agonist [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02250105) Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe ( 00 mg/dl) Hypertriglyceridemia. U.S. National Institutes of Health.
3 2011 Pipeline of Arisaph Pharmaceuticals.